Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $48.5 million.

  • CorMedix's Cash & Equivalents rose 3742.81% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 3742.81%. This contributed to the annual value of $40.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that CorMedix reported Cash & Equivalents of $48.5 million as of Q3 2025, which was up 3742.81% from $159.3 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Cash & Equivalents peaked at $159.3 million during Q2 2025, and registered a low of $19.7 million during Q2 2023.
  • Its 5-year average for Cash & Equivalents is $53.4 million, with a median of $46.9 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 52447.61% in 2021, then crashed by 5973.92% in 2023.
  • CorMedix's Cash & Equivalents (Quarter) stood at $53.3 million in 2021, then dropped by 19.07% to $43.1 million in 2022, then grew by 23.56% to $53.3 million in 2023, then fell by 23.75% to $40.7 million in 2024, then increased by 19.29% to $48.5 million in 2025.
  • Its Cash & Equivalents was $48.5 million in Q3 2025, compared to $159.3 million in Q2 2025 and $66.3 million in Q1 2025.